Eslicarbazepine-induced hyponatremia: A retrospective single-center real clinical practice study.
eslicarbazepine
hyponatremia
risk factor
Journal
Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
received:
27
06
2023
accepted:
15
08
2023
pubmed:
18
8
2023
medline:
18
8
2023
entrez:
18
8
2023
Statut:
aheadofprint
Résumé
Hyponatremia is a typical side effect of antiseizure drugs from the dibenzazepine family. The study investigated the prevalence of hyponatremia in patients with epilepsy who were treated with eslicarbazepine. We aimed to determine the prevalence of hyponatremia, reveal the factors leading to the discontinuation of treatment, and identify possible risk factors for the development of hyponatremia including the dose dependency. The medical records of 164 patients with epilepsy taking eslicarbazepine in our center were analyzed. The overall prevalence of hyponatremia was 30.5%. The prevalence of mild hyponatremia, seen in 14%-20% of patients, was not dose dependent. The prevalence of moderate and severe hyponatremia was significantly dose dependent. The severity of hyponatremia was significantly dose dependent. Severe hyponatremia was found in 6.1% of patients. Hyponatremia was asymptomatic in the majority of cases, and in 48% did not require any management. Hyponatremia was the reason for discontinuation in 6.2% of patients. The major risk factor for developing hyponatremia was older age. The study shows that eslicarbazepine-induced hyponatremia is usually mild and asymptomatic. It usually does not require any management and seldom leads to treatment discontinuation. Hyponatremia is dose dependent. Another major risk for developing hyponatremia (besides dose) is older age.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : LX22NPO5107
Informations de copyright
© 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Berghuis B, van der Palen J, de Haan GJ, et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 2017;58(7):1227-1233.
Gupta DK, Bhoi SK, Kalita J, Misra UK. Hyponatremia following eslicarbazepine therapy. Seizure. 2015;29:11-14.
Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005;65(12):1976-1978.
Villanueva V, Serratosa JM, Guillamón E, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res. 2014;108(7):1243-1252.
Sperling MR, Abou-Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56(2):244-253.
Hufnagel A, Ben-Menachem E, Gabbai AA, Falcão A, Almeida L, Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res. 2013;103(2-3):262-269.
Intravooth T, Staack AM, Juerges K, Stockinger J, Steinhoff BJ. Antiepileptic drugs-induced hyponatremia: review and analysis of 560 hospitalized patients. Epilepsy Res. 2018;143:7-10.
Habib MB, Elshafei M, Ali E, et al. Eslicarbazepine-induced severe hyponatremia resulted in generalized tonic-clonic seizure. Clin Case Rep [Internet]. 2021;9(11). Accessed June 10, 2023. https://onlinelibrary.wiley.com/doi/10.1002/ccr3.4851
Kim YS, Kim DW, Jung KH, et al. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure. 2014;23(3):208-212.
Gandhi S, McArthur E, Mamdani MM, et al. Antiepileptic drugs and hyponatremia in older adults: two population-based cohort studies. Epilepsia. 2016;57(12):2067-2079.
Burst V. Etiology and epidemiology of hyponatremia. In: Peri A, Thompson CJ, Verbalis JG, editors. Frontiers of Hormone Research [Internet]. S. Karger AG; 2019. p. 24-35. Accessed June 10, 2023. https://www.karger.com/Article/FullText/493234
Shysh AC, Ismail Z, Sidhu D, Guo M, Nguyen LT, Naugler C. Factors associated with hyponatremia in patients newly prescribed citalopram: a retrospective observational study. Drugs Real World Outcomes. 2021;8(4):555-563.